

**UNCLASSIFIED**

**AD NUMBER**

**ADB254260**

**NEW LIMITATION CHANGE**

**TO**

**Approved for public release, distribution  
unlimited**

**FROM**

**Distribution authorized to U.S. Gov't.  
agencies only; Proprietary information;  
Sep 1999. Other requests shall be referred  
to U.S. Army Medical Research and Materiel  
Command, 504 Scott Street, Fort Detrick,  
MD, 21702-5012.**

**AUTHORITY**

**USAMRMC ltr, 5 Mar 2002**

**THIS PAGE IS UNCLASSIFIED**

# REPORT DOCUMENTATION PAGE

**Form Approved  
OMB No. 074-0188**

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|   |  |   |  |
|---|--|---|--|
| 1. AGENCY USE ONLY (Leave blank)  | 2. REPORT DATE   | 3. REPORT TYPE AND DATES COVERED                        |  |
|   | September 1999   | Annual (1 Sep 98 - 31 Aug 99)                           |  |
| 4. TITLE AND SUBTITLE<br>Role of the DIP Molecules in DCC Signaling   |  |   | 5. FUNDING NUMBERS<br>DAMD17-98-1-8501           |
| 6. AUTHOR(S)<br>Yong Q. Chen, Ph.D.   |  |   |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Wayne State University<br>Detroit, Michigan 48202   |  |   | 8. PERFORMING ORGANIZATION REPORT NUMBER         |
| E-MAIL:<br>yqchen@med.wayne.edu   |  |   |  |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012   |  |   | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER |
| 11. SUPPLEMENTARY NOTES   |  |   |  |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br>Distribution authorized to U.S. Government agencies only (proprietary information, Sep 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.   |  |   | 12b. DISTRIBUTION CODE                           |
| <p>Inactivation of tumor suppressor genes plays a causal role in the development of human cancers. The Deleted in Colorectal Cancer (DCC) gene is a putative tumor suppressor gene. Loss of heterozygosity at the DCC locus and loss of DCC expression has been observed in prostate cancer. Our recent data indicate that DCC expression induces apoptosis and cell cycle arrest of prostate tumor cells. By yeast two-hybrid screening, we have identified molecules that interact with the DCC cytoplasmic domain (dubbed DCC interacting proteins or DIPs). We hypothesize that the cytoplasmic domain of DCC transduces a signal resulting in either activation of caspase which induces apoptosis or inhibition of Cdk1 kinase activity which leads to G2/M cycle arrest, and this signal of DCC is mediated by the DIPs. To understand the mechanism by which DCC induces apoptosis and cycle arrest, we propose to study the role of DIPs in DCC signaling. In the last 12 months, we have partially completed our task1. Moreover, we performed extra experiments by cloning two novel genes. The major accomplishments are (1) Truncation of the DCC cytoplasmic domain; (2) Tagging of DCC and hsina, FKBP12; (3) Cloning of two novel genes, Dip5 and Dip13 and (4) Tagging Dip5 and Dip13.</p> |  |   |  |
| 14. SUBJECT TERMS<br>Prostate Cancer, DCC, Apoptosis, cell cycle  |  |   | 15. NUMBER OF PAGES<br>19                        |
|   |  |   | 16. PRICE CODE                                   |
| 17. SECURITY CLASSIFICATION OF REPORT<br>Unclassified   | 18. SECURITY CLASSIFICATION OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Unlimited          |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

20000530 080

AD

Award Number: DAMD17-98-1-8501

TITLE: Role of the DIP Molecules in DCC Signaling

PRINCIPAL INVESTIGATOR: Yong Q. Chen, Ph.D.

CONTRACTING ORGANIZATION: Wayne State University  
Detroit, Michigan 48202

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Sep 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

## NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

### LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8501

Organization: Wayne State University

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Approved for Pub  
S/20

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

       Where copyrighted material is quoted, permission has been obtained to use such material.

       Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

       Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

9/21/99

Date

## **Table of Contents**

|                                   |           |
|-----------------------------------|-----------|
| Front Cover .....                 |           |
| Report Documentation .....        | Page 2    |
| Foreword .....                    | Page 3    |
| Table of Contents.....            | Page 4    |
| Introduction .....                | Page 5    |
| Body .....                        | Page 6-7  |
| Key Research Accomplishment ..... | Page 7    |
| Reportable Outcomes .....         | Page 7    |
| Conclusions .....                 | Page 7    |
| References .....                  | Page 8    |
| Appendix .....                    | Page 8-18 |

## Introduction

Tumor formation arises as a consequence of alterations in the control of cell proliferation and disorders in the interaction between cells and their surroundings. Uncontrolled cell proliferation is generally considered the result of oncogene activation and tumor suppressor gene inactivation, whereas alterations in cell-cell and cell-environment interactions are due in part to the malfunction of cell adhesion molecules. Interestingly the putative tumor suppressor gene DCC, encoding a cell adhesion molecule, may play a dual role.

Previously, we studied the DCC gene and its mRNA expression in human and rat prostatic carcinoma cells as well as in prostatic carcinoma tissues by RT-PCR and PCR-LOH (Gao et al, 1993). The DCC gene was present and expressed in normal prostatic cells. However, its expression was decreased or undetectable in all prostatic carcinoma cell lines either from human [4 cell lines] or rat [5 cell lines]. In patients, 12 out of 14 cases [86%] showed reduced DCC expression and 5 out of 11 informative cases [45%] showed loss of heterozygosity at the DCC locus. These results demonstrate that loss of DCC expression and loss of heterozygosity at the DCC locus are frequent features of prostatic carcinoma.

Recently, we have found that DCC expression induces apoptosis or cell cycle arrest of human prostate tumor cells. Human DCC was expressed in DU145 and PC-3 carcinoma cells. Expression of DCC rapidly induced apoptosis of DU145 but not of PC-3 cells (Chen et al., 1999 and appendix 1). DNA fragmentation could be seen within 24 hours of DCC expression in DU145 cells. Apoptotic cells appeared starting at 18 hours of DCC expression and more than 90% of cells were apoptotic and floating at 48 hours. The morphological appearance of apoptotic cells coincided with the cleavage of poly (ADP-ribose) polymerase. Our results indicate that DCC-induced apoptosis is a rapid process, likely involving the activation of caspases. In PC-3 cells, DCC expression resulted in a flattened, enlarged morphology resembling G1 arrested cells. However, cell cycle distribution analysis by flow cytometry showed that cells were arrested at the G2/M phase. Furthermore, we found that DCC expression inhibited the Cdk1 kinase activity (Chen et al., 1999 and appendix 1)..

In order to identify potential DCC signaling mediators, we used the DCC cytoplasmic domain as the bait in yeast interaction trap screening. Thirteen DCC interacting proteins (DIPs) were identified. Four of the DIPs are novel genes.

Based on our preliminary studies, we propose a hypothetical signaling pathway(s) of DCC. An increasing level of DCC expression triggers DCC protein clustering. Depending upon cell genetic background, the cytoplasmic domain of the DCC protein then transduces signals resulting either in activation of caspases which induces apoptosis, or in inhibition of Cdk1 kinase activity which leads to G2/M cycle arrest.

The purpose of this study was to investigate the role of DCC interacting molecules (DIPs) in DCC signaling in human prostate carcinoma cells.

## Body

There were two aims in our proposal, i.e. (1) confirm the interaction of DCC with DIPs and (2) determine the necessity of DCC and DIP interaction in DCC-induced apoptosis and cell cycle arrest. We divided our work into two main tasks:

Task 1. Confirm the interaction of DCC with DIPs (month 1-15).

- Tagging of the DCC cytoplasmic domain, hsina and FKBP12 by PCR and sequencing to assure there is no mutation due to mis-incorporation.
- Transfection, immunoprecipitation and western analysis in prostate cells
- Generate N- and C-terminus truncated DCC cytoplasmic domain vectors
- Yeast two-hybrid assay using hsina, FKBP12 and the truncated DCC cytoplasmic domain.
- Confirm the interaction site(s) identified above in prostate cells

Task 2. Determine the necessity of DCC and DIP interaction in DCC-induced apoptosis and cell cycle arrest (month 16-30).

- Generate of DCC mutant(s) that lack hsina and/or FKBP12 interacting site.
- Generate, characterize, amplify and titrate recombinant DCC mutant adenovirus.
- Express wild-type and mutant DCC in DU145 and PC-3 cells. Monitor apoptosis by light microscopy, DAPI staining, DNA laddering, flow cytometry and cleavage of PARP as well as cell cycle arrest by flow cytometry and Cdk1 kinase assay.
- Establish tetracycline-inducible hsina and FKBP12 expression cell lines.
- Monitor apoptosis by light microscopy, DAPI staining, DNA laddering, flow cytometry and cleavage of PARP as well as cell cycle arrest by flow cytometry and Cdk1 kinase assay.

During the past 12 months, we have published a paper in the journal of Oncogene (Appendix 1).

We have successfully generated N- and C-terminus truncated DCC cytoplasmic domain vectors. A total of 10 different vectors were constructed according to our experiment design (Fig. 1).




Fig. 1. Truncation of the DCC cytoplasmic domain.

We have completed the tagging of DCC cytoplasmic domain, hsina and FKBP12 by PCR and sequencing to assure there is no mutation due to mis-incorporation. DCC, hsina and FKBP12 were tagged with HA and Flag epitopes.

We have cloned two novel genes, i.e. Dip5 and Dip13. A total of 1735 bp were obtained for Dip5 which has an ORF of 1296 bp encoding for 432 amino acids (Appendix 2). A total of 1683 bp were obtained for Dip13 which has an ORF of 603 bp encoding for 200 amino acids (Appendix 3). Both Dip5 and Dip13 have been tagged with Flag and V5 epitopes.

In summary, we have partially completed the task1. In addition, we performed extra experiments by cloning two novel genes.

## Key research accomplishments

- Truncation of the DCC cytoplasmic domain
- Tagging of DCC and hsina, FKBP12
- Cloning of two novel genes, Dip5 and Dip13.
- Tagging Dip5 and Dip13

## Reportable outcomes

- One manuscript (Appendix 1)
- Apply for one patent

## Conclusions

Previously, we observed loss of heterozygosity at the DCC locus and loss of DCC expression in both human prostate tumor tissues and prostate carcinoma cell lines, indicating that inactivation of the DCC gene may contribute to prostate cancer development. We now show that forced expression of DCC induces G2/M cell cycle arrest and apoptosis of prostate carcinoma cells. By yeast two-hybrid screening, we have identified several molecules that interact with the DCC cytoplasmic domain. During the first 12 months, we have generated reagents and cloned two novel genes which will enable us to investigate the role of Dip molecules in mediation of the apoptotic and/or cycle arrest signal of DCC. Potential impacts of such study are two-fold.

First, our study should allow us to understand better the function of DCC and the signaling mechanism of DCC-induced apoptosis and G2/M cycle arrest in prostate cells. Should loss of DCC function be confirmed to play a role in prostate cancer development, inactivation of DCC may serve as a prognostic/diagnostic marker for prostate cancer progression.

Second, since DCC expression induces cell cycle arrest and apoptosis of prostate tumor cells, the DCC gene may be used for prostate cancer gene therapy, once the DCC signaling mechanism is better defined.

## References

Gao, X., Honn, K., Grignon, D., Sakr, W., Chen, Y. Q. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinoma. *Cancer Res.* 53: 2723-2727, 1993.

Chen, Y. Q., Hsieh, J. T., Yao, F., Fang, B., Pong, R., Cipriano, S. C., Krepulat F. Induction of apoptosis and G2/M cell cycle arrest by DCC. *Oncogene*, 18: 2747-2754, 1999.

## Appendix

1. Manuscript. *Oncogene*, 18: 2747-2754, 1999
2. cDNA sequence of Dip 5 (unpublished data)
3. cDNA sequence of Dip 13 (unpublished data)



## Induction of apoptosis and G2/M cell cycle arrest by DCC

Yong Q Chen<sup>\*1</sup>, Jer-Tsong Hsieh<sup>2</sup>, Fayi Yao<sup>1</sup>, Bingliang Fang<sup>3</sup>, Rej-chin Pong<sup>2</sup>, Sherry C Cipriano<sup>1</sup> and Frauke Krepulat<sup>1</sup>

<sup>1</sup>Department of Pathology, Wayne State University, Detroit, Michigan 48201, USA; <sup>2</sup>Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75235, USA; <sup>3</sup>Department of Thoracic Surgery, MD Anderson Cancer Center, Houston, Texas 77030, USA

The Deleted in Colorectal Cancer gene (DCC) encodes a cell surface receptor that belongs to the Ig superfamily. Inactivation of the DCC gene has been implicated in human tumor progression. However, little is known about the biological function of the DCC protein. In the present study, we demonstrated that expression of DCC activated caspase-3 and programmed cell death, or induced G2/M cell cycle arrest in tumor cells. In some cell lines, apoptosis was evident within 24 h of DCC expression. Timing of the appearance of apoptotic cells coincided with that of the cleavage of poly (ADP-ribose) polymerase, a substrate of caspase-3. Expression of the apoptosis inhibitory gene Bcl-2 was not able to abrogate the DCC-induced apoptosis. In the G2/M cycle arrest cells, cdk1 activity was inhibited. Our results suggest that the DCC protein may transduce signals resulting in activation of caspases or inhibition of Cdk1. These data provide a possible mechanism by which DCC suppresses tumorigenesis.

**Keywords:** DCC; apoptosis; caspase; tumor suppressor gene; cell cycle; Cdk1

### Introduction

Deleted in Colorectal Cancer (DCC) was originally identified by virtue of its high frequency of deletion in colon carcinoma. The DCC gene was mapped to chromosome 18q21.2 and isolated by positional cloning (Fearon *et al.*, 1990; Cho *et al.*, 1994). Deduced amino acid sequence shows a high homology with the neural cell adhesion molecule (N-CAM) and other related cell surface glycoproteins of the Ig superfamily (Fearon *et al.*, 1990; Cho *et al.*, 1994). Frequent loss of heterozygosity at the DCC locus and loss of DCC expression have been observed in human colon (Fearon *et al.*, 1990; Thiagalingam *et al.*, 1996) and prostate carcinomas (Gao *et al.*, 1993) as well as in pancreatic, gastric, esophageal, bladder, breast, head and neck carcinomas and male germ cell tumors, neuroblastoma, glioma, hematologic malignancy (Fearon, 1996, references therein). These results suggest that inactivation of the DCC gene may be involved in the development of human cancers. However, the biological function of DCC is still largely unknown.


Recently, the tumor suppressor gene Deleted in Pancreatic Cancer (DPC4 or smad4) has been cloned and shown to play an important role in TGF- $\beta$  signaling. The DPC4 (smad4) gene is located in close proximity to the DCC locus on chromosome 18q. Because of this close proximity and the uncertainty of DCC function, there was a question whether DPC4 rather than DCC is the tumor suppressor gene that is inactivated in colon carcinoma cells. In order to address this question, the loss of heterozygosity at 18q has been re-evaluated in colon tumor samples (Thiagalingam *et al.*, 1996). The results suggest that the DCC, but not the DPC4, is the most frequently altered gene on chromosome 18q13.3-21.3. In this study, we found that forced DCC expression induces apoptosis or cell cycle arrest, providing a potential mechanism of DCC action.

### Results and discussion


In order to determine the function of DCC, human DCC cDNA was expressed in colon DLD-1 and prostate DU145, PC-3 carcinoma cells by recombinant adenovirus infection. Mock and control adenovirus-infected DLD-1, DU145 and PC-3 cells did not express a detectable level of DCC, whereas the 180 kD DCC protein was easily detected in DCC adenovirus-infected cells (Figure 1a). Expression of DCC rapidly induced apoptosis of DLD-1 and DU145 but not PC-3 cells. DNA fragmentation could be seen within 24 h of DCC expression in DLD-1 and DU145 cells (Figure 1b). DNA fragmentation was also evident by flow cytometry analysis of DNA content. At 48 h postinfection, mock and control adenovirus-infected DU145 cells had a similar G1, S and G2/M phase distribution, whereas DCC adenovirus-infected DU145 cells had a large population of cells with DNA contents smaller than G1 phase cells (Figure 1c), a characteristic of apoptotic cells. DCC protein expression in DU145 cells was detectable at 12 h and reached a plateau approximately 30 h postinfection (Figure 2a). Apoptotic cells could be seen starting at 18 h postinfection and more than 90% of cells were apoptotic and floated at 48 h postinfection (Figure 2b). The morphological appearance of apoptotic cells coincided with the cleavage of poly (ADP-ribose) polymerase (Figure 2c). It has been demonstrated that proteolytic cleavage of PARP by caspases is a widespread phenomenon in cells undergoing apoptosis (Kaufman *et al.*, 1993; Lazebnik *et al.*, 1994; Nicholson *et al.*, 1995; Tewari *et al.*, 1995). Similar kinetics of DCC-induced programmed cell death was observed in DLD-1 cells (data not shown).

\*Correspondence: YQ Chen

Received 4 November 1997; revised 16 December 1998; accepted 16 December 1998




**Figure 1** Induction of apoptosis by DCC. (a) Cells were mock-infected (lane 1) and infected at MOI 5 with a control adenovirus dl312 (lane 2) or AdDCC adenovirus (lane 3). Cells were collected 24 h postinfection, lysed and used for Western detection of DCC. Membrane was stripped and reprobed for  $\beta$ -actin to show protein loading. (b) Cells ( $1 \times 10^6$ ) were mock-infected (lane 1), and infected at MOI 5 with control adenovirus AdCMV (lane 2), dl312 (lane 3) or AdDCC (lane 4). Samples were collected at 24 and 48 h postinfection and used for DNA fragmentation assay. (c) DU145 cells ( $2 \times 10^6$ ) were mock infected or infected at MOI 5 with control adenovirus AdCMV, dl312 and AdDCC. Cells were collected at 48 h postinfection, fixed and analysed for cell cycle distribution



**Figure 2** Kinetics of DCC-induced apoptosis in DU145 cells. Cells ( $1 \times 10^6$ ) were seeded in 100-mm culture dish each containing a coverslip. Next day, cells were mock-infected or infected with dl312 and AdDCC at MOI 5 in 2 ml culture medium for 1 h at 37°C with shaking every 10 min. Three ml medium were added after infection. Cells were collected at 6 h intervals for a period of 48 h for Western detection of DCC and  $\beta$ -actin protein (a), at which point cell morphology was monitored by light microscopy (b; phase contrast photos). Cells attached to the coverslip were fixed and used for DAPI staining (b; fluorescent photos). Cell samples collected in the experiment A were also used for the analysis of PARP cleavage. The 116 kD PARP protein and the 85 kD apoptosis-related cleavage fragment were detected by Western blotting (c)

Our results indicate that the DCC-induced apoptosis is a rapid process, likely involving the activation of caspases. A loss of DCC expression is a common feature in many cancer cells. However, the levels of DCC mRNA and protein are usually very low in normal tissues, to the point that they are hardly detectable by Northern and Western blotting. Immunostaining of human colon tissue indicates that DCC is expressed only in the fully differentiated epithelial secretory cells, the goblet cells, and in late-stage adenomas and in nonmucinous carcinoma, DCC expression is lost (Hedrick *et al.*, 1992). In order to compare the level of DCC expression in our experimental system to that *in vivo*, human colon

carcinoma DLD-1 cells were infected with AdDCC or dl312. The cells were collected at 18 h post-infection. Cell samples as well as human intestinal tissue sections were simultaneously used for immunostaining of the DCC protein. The secretory cells of intestinal tissue and AdDCC-infected cell culture gave strong DCC staining (Figure 3a). The intensity of DCC protein staining was quantified by optical densitometry (Figure 3b). The mean value for the negative control sample was 64, for secretory cells 294 and for AdDCC-infected DLD-1 cells 259. These results indicate that, under our experimental condition, adenoviral mediated expression of DCC in culture results in a level of the DCC protein, which is comparable to that in human




**Figure 3** Comparison of DCC protein level *in vitro* and *in vivo*. (a) Human intestinal tissue sections were incubated with anti-DCC cytoplasmic domain monoclonal antibody (upper left panel) or normal mouse IgG (lower left panel), followed by anti-mouse IgG conjugated with peroxidase antibody. DLD cells were infected with AdDCC (middle panels) or dl312 (right panels) at MOI 5. Cells were collected 18 h post-infection and incubated with anti-DCC cytoplasmic domain monoclonal antibody (upper middle and upper right panels) or normal mouse IgG (lower middle and lower right panels), followed by anti-mouse IgG conjugated with peroxidase antibody. Note that DCC expression (red color) is restricted to secretory cells in mucosa. (b) The intensity of DCC protein staining was determined by the Becton Dickinson CAS 200 Cell Analysis System. The cytoplasmic area of 100 individual cells from each sample was measured and the total pixel histograms for control, human tissue and DLD-1 cells infected with AdDCC (moi 5) were shown. OD: optical density. P: OD higher than the P value was considered positive

intestinal secretory cells. It is well known that the fully differentiated epithelial cells of the GI tract have a rapid turnover rate, i.e. cells die within 2–3 days. Therefore, it is possible that DCC is only expressed to a high level during the differentiation of basal epithelial cells to secretory cells, resulting in rapid cell death. Thus DCC may function as an apoptosis inducer in human tissue.

It is known that some members of the Bcl-2 gene family can inhibit or delay apoptosis stimulated by a variety of signals (White, 1996; Oltvai and Korsmeyer, 1994; Boise *et al.*, 1993). To determine whether expression of Bcl-2 or Bcl-xL can inhibit DCC-induced apoptosis, SHEP-1 cell, an epitheloid subclone of the human neuroblastoma line SK-N-SH, and SHEP-1 clones expressing Bcl-2 or Bcl-xL were infected with control adenovirus, DCC adenovirus or mock-infected. Programmed cell death was determined at different time points by cell morphology and DNA

fragmentation assay. Forced DCC expression induced apoptosis of SHEP-1 cell and clones expressing Bcl-2 or Bcl-xL (data not shown). This result suggests the possibility that Bcl-2 or Bcl-xL may not be able to block DCC-induced programmed cell death. To confirm this observation, DU145 and DLD-1 cells were transfected with a Bcl-2 expression vector (pcDNA Bcl-2-flag) and control vector (pcDNA3). Pooled populations as well as individual colonies of Neo and Bcl-2 were obtained. No Bcl-2-flag epitope were detected in pooled Neo populations of DU145 and DLD-1 cells (Figure 4a). However, the Bcl-2-flag protein was easily detectable in pooled Bcl-2 populations and individual colonies of DU145 and DLD-1 cells (Figure 4a). No endogenous Bcl-2 protein was detected in DU145 cells (Figure 4a), a result similar to that described by another group (Halder *et al.*, 1996). Endogenous Bcl-2 protein, at a lower molecular weight than that of the transfected Bcl-2-flag protein, was seen



**Figure 4** Effect of Bcl-2 on DCC-induced apoptosis. DLD-1 and DU145 cells were transfected with pcDNA3 or pcDNA Bcl-2-flag vector and selected with G418. Pooled population as well as individual clones were obtained. Expression of the Bcl-2-flag protein was determined by Western blotting using anti-flag and anti-Bcl-2 antibodies (a). Neo<sup>R</sup> and Bcl-2 expressing DU145 and DLD-1 cells were mock infected, infected with dl312, AdDCC at MOI 5 or treated with 300 µM (DU145) or 500 µM (DLD-1) of H<sub>2</sub>O<sub>2</sub>. Cell morphology was monitored at 48 h post-treatment (b). Cells infected with dl312 and AdDCC were lysed and used for Western detection of PARP cleavage (c). No: mock treated. Neo-pp: pooled population of G418 resistant clones. Bcl-2-pp: pooled population of Bcl-2-transfected clones. Bcl-2-1: clone number 1 of Bcl-2-transfected cells

in DLD-1 cells (Figure 4a). Bcl-2 expression protected DU145 and DLD-1 cells from apoptosis induced by H<sub>2</sub>O<sub>2</sub> (Figure 4b), indicating that the transfected Bcl-2 protein is functional. However, the functional Bcl-2 expression did not protect DU145 and DLD-1 cells from apoptosis induced by DCC (Figure 4b). PARP cleavage could be seen in the pooled Neo or Bcl-2 populations as well as individual Bcl-2 colonies of DU145 and DLD-1 cells (Figure 4c). Nevertheless, Bcl-2 expression reduced the ratio of the cleaved 85 kD to the intact 116 kD PARP (Figure 4c). These results suggest that the DCC-induced apoptosis process cannot be blocked, but may be slightly slowed down by Bcl-2.


To determine whether induction of apoptosis by DCC is a general phenomenon, we studied a total of twenty-two cell lines. These included three prostate carcinoma, one colon carcinoma, four breast carcinoma, three neuroblastoma, three osteosarcoma, one cervical carcinoma, five bladder carcinoma cell lines and one immortal breast epithelial and one immortal keratinocyte cell line. DCC expression induced either apoptosis or cell cycle arrest in all cell lines studied. The cells, based on their response to DCC, can be categorized into three groups: (a) rapid induction of apoptosis, (b) irreversible cell cycle arrest followed by apoptosis and (c) transient cell cycle arrest.

The DCC gene encodes a cell surface receptor of the Ig superfamily (Fearon *et al.*, 1990). Molecules of the Ig family can mediate cell-cell and cell-matrix interactions through a homotypic (i.e. receptor interacts with the same receptor) or a heterotypic fashion (i.e. receptor interact with a ligand or another receptor). So far, no homotypic interaction of DCC has been confirmed. However, it has been shown that

DCC is a candidate component of the receptor for netrin-1 (Keino-Masu *et al.*, 1996; Chan *et al.*, 1996; Kolodziej *et al.*, 1996). Therefore, we also evaluated whether netrin-1 can stimulate or inhibit DCC-induced apoptosis. DU145 cells were infected with control, DCC adenovirus or mock infected in the absence or presence of netrin-1 protein. The kinetics of apoptosis was monitored by DNA fragmentation and microscopy. Our results indicate that exogenous netrin-1 protein has no effect on the DCC-induced apoptosis (data not shown). However, it was not clear whether all of DCC receptors were occupied by the netrin-1 protein under our experimental conditions.

Cell surface receptors usually transduce their signal through the cytoplasmic domain. To address the role of the cytoplasmic domain of DCC in inducing apoptosis, we generated recombinant adenovirus of a DCC mutant that lacks its cytoplasmic domain (Figure 5a). Successful expression of the mutant DCC was confirmed by Western (Figure 5b). Next, we determined the ability of this DCC mutant to induce apoptosis. We found that the wild-type DCC but not the mutant induced apoptosis, activated caspase-3 (Figure 5c and d). Our results demonstrate that the cytoplasmic domain is required for DCC to induce apoptosis, and confirm the involvement of caspase-3 in DCC-induced apoptosis.

As mentioned earlier, DCC expression did not induce apoptosis of PC-3 cells. Instead, DCC expression resulted in PC-3 cells with a flattened, enlarged morphology resembling G1 arrested cells. To determine whether DCC expression induces cell cycle arrest in some cell lines, human prostate carcinoma PC-3, osteosarcoma HOS and breast carcinoma MCF-7 cells were infected with the AdDCC adenovirus,



**Figure 5** Requirement of the DCC cytoplasmic domain in inducing apoptosis. (a) structure of the wild-type DCC and a mutant without the cytoplasmic domain. (b) DU145 cells were infected with AdDCC or AdΔcyto at MOI 5. Samples were collected at 24 h post-infection and used for western detection of DCC with an anti-DCC extracellular domain antibody. C: DU145 cells ( $1 \times 10^6$ ) were infected with AdDCC, AdΔcyto at MOI 5 or mock infected. Samples were collected at 24 h post-infection and used for western detection of the active form of the caspase-3 protein. (d) samples from C were used for caspase-3 activity assay (bars) using a CPP32 colorimetric assay kit (Clontech). Caspase-3 specific inhibitor used was DEVD peptide. RLU stands for relative light unit. Bar represents standard deviations

AdCMV and dl312 control adenovirus or mock-infected. Samples were collected 72 h post-infection and used for cell cycle distribution analysis by flow cytometry. Mock and control adenovirus-infected cells had a similar G1, S and G2/M phase distribution, whereas DCC adenovirus-infected cells were arrested at the G2/M phase (Figure 6a). The G2/M population increased by more than twofold at 72 h post-infection of AdDCC in the asynchronous culture of PC-3, HOS and MCF-7 cells (Figure 6b) and cells were growth arrested (Figure 6c). Our data indicate that DCC expression induces a rapid G2/M cell cycle arrest in some cell lines.


Due to the nature of flow cytometry, we were uncertain whether DCC expression arrested cells at the G2 or the prophase, metaphase, anaphase or telophase of the cell division. To differentiate between these possibilities, PC-3 cells were infected with AdDCC, dl312 control adenovirus or mock-infected. Cells were fixed 72 h post-infection and used for immunocytochemistry analysis using an anti-DCC antibody. DCC expressing cells had a flatter morphology (Figure 7a) compared to the dl312 control- (Figure 7b) or mock-infected cells (data not shown). Cell nuclei were stained

with DAPI. The nuclei of DCC expressing cells had an intact nuclear membrane and slightly condensed chromatin (Figure 7b and insert), a characteristic of early prophase cells. These results suggest that DCC expressing cells were arrested at the later G2/early prophase of mitosis. Three groups of molecules, i.e. cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors, have been identified and they are the key molecules in controlling cell cycle progression (Hunter and Pines, 1994). All the inhibitors identified so far are primarily involved in G1 control. Cdk4 and Cdk6, in association with cyclin D, are important in G1 progression. Cdk2, in association with cyclin E or cyclin A, is critical for G1 to S transition and S phase progression. Cdk1 (also known as Cdc2) in association with cyclin B is required for cell mitosis (Nurse, 1994; King *et al.*, 1994; Dunphy, 1994). The prophase cell cycle arrest by DCC may be due to an inhibition of Cdk1 activity. Therefore, Cdk1 kinase activity was compared in AdDCC-, control adenovirus- and mock-infected cells. Indeed, we found that DCC expression inhibited the Cdk1 kinase activity (Figure 7i).


DCC was suggested as a tumor suppressor. Recently, the mouse homologue of DCC has been

knocked out (Fazeli *et al.*, 1997). Mice homozygous for the *Dcc*<sup>-</sup> died within 24 h after birth, and showed defects in axonal projections. No alterations in growth, differentiation, morphogenesis or tumorigenesis of

intestine were observed in both homozygous and heterozygous mice as well as in *Dcc*<sup>+/+</sup>↔*Dcc*<sup>-/-</sup> chimeras. These results fail to support a tumor suppressor function for DCC. However, the lack of



**Figure 6** DCC-induced G2/M cell cycle arrest. (a) PC-3 cells were infected with AdCMV or d1312 control adenovirus, AdDCC adenovirus or mock-infected. Cells were collected 72 h post-infection and used for flow cytometry analysis. (b) Percentage of the G2/M population in mock-, d1312 control- and AdDCC adenovirus-infected PC-3, MCF-7 and HOS cells. Samples were analysed at 72 h post-infection. C: PC-3 cells were infected with AdDCC, d1312 at MOI 5 or mock infected. Number of cells was counted daily for a period of 6 days. Three samples were used for each point and three independent experiments were performed. Bar represents standard deviations



**Figure 7** Morphological features and Cdk1 activity of cells arrested by DCC. PC-3 cells were infected with d1312 or AdDCC adenovirus at multiplicity of infection 5. Cells were fixed at 72 h post-infection and used for immunocytochemistry. (a) phase contrast image of AdDCC-infected cells, (b) DAPI staining (blue color) of AdDCC-infected cells, (c) DCC staining (red color) of AdDCC-infected cells, (d) composite of DAPI and DCC staining of AdDCC-infected cells, (e) phase contrast image of d1312-infected cells, (f) DAPI staining (blue color) of d1312-infected cells, (g) DCC staining of d1312-infected cells, (h) composite of DAPI and DCC staining of d1312-infected cells, (i) PC3, HOS and MCF7 cells were mock-infected (2) or infected with d1312 control adenovirus (3) and AdDCC (4) at MOI 5. Samples were collected at 72 h post-infection and 500 µg of total protein were used for immunoprecipitation with anti-Cdk1 antibody, then for histone H1 phosphorylation assay. The upper panels show the phosphorylation of histone H1 by Cdk1, the lower panels show the loading of histone H1 protein. To show the specificity of kinase activity assay, 500 µg of mock-infected PC3 protein were immunoprecipitated with anti-Cdk1 antibody in the presence of 1 µg of Cdk1 immunogen peptide (1)

tumor in homozygous mice may be due to the early death of offspring. The result from heterozygous mice should be interpreted with caution. For example, heterozygous mice for BRCA1 or BRCA2 gene did not manifest defects or an increased rate of tumorigenesis (Liu *et al.*, 1996; Hakem *et al.*, 1996; Sharan *et al.*, 1997). In addition, the phenotype of a tumor suppressor gene loss in human may not be mimicked by the phenotype in mice. For instance, more than 50% of human colorectal tumors have a loss of function of the tumor suppressor gene p53. Yet, no colon tumor could be seen in p53 knockout mice (Donehower *et al.*, 1992). Therefore, it is still uncertain whether the DCC is a tumor suppressor gene. In fact, our data on induction of apoptosis and cell cycle arrest by DCC argue for a tumor suppressor function of DCC.

Interestingly, forced DCC expression induces programmed cell death and/or cell cycle arrest of tumor cells regardless of their p53 and Rb status, i.e. wild-type, mutant or null. The DCC protein is a cell surface receptor. So far two other cell surface receptors, Fas and TNFR1, have been shown to be capable of inducing apoptosis. The Fas/TNFR1 apoptotic signals are transduced by a cascade of molecular interactions involving TRADD, FADD and FLICE (Cleveland and Ihle, 1995; Fraser and Evan, 1996). These molecules interface through a highly homologous region termed death domain. However, no death domain or an obvious death domain homology can be identified in the cytoplasmic portion of the DCC protein. Therefore, it would be of great interest to define the pathway by which DCC induces apoptosis and cell cycle arrest.

## Materials and methods

### Cells

Human prostate carcinoma DU145, PC-3, LNCaP cells were cultured in RPMI 1640 with 5% FBS, colon carcinoma DLD-1 in DMEM with 5% FBS, breast carcinoma MCF7 cells in DMEM with 5% FBS, 10 µg/ml insulin, osteosarcoma HOS in RPMI 1640 with 10% FBS. Cell numbers were counted with the trypan blue exclusion method in a hemacytometer.

### Western blotting

Detection of DCC, β-actin, poly (ADP-ribose) polymerase, caspase-3, Bcl-2 and the flag epitope were performed as described previously (Chen *et al.*, 1995) with a monoclonal anti-DCC C-terminus antibody (PharMingen), a monoclonal anti-actin antibody (Sigma), the monoclonal C-2-10 anti-PARP antibody (Biomol), a monoclonal anti-caspase-3 (PharMingen), a monoclonal anti-Bcl-2 (DAKO) antibody and the M2 monoclonal anti-Flag antibody (Eastman Kodak).

### Recombinant adenovirus

Human DCC cDNA was cloned into the shuttle vector pAdE1CMV/pA. Recombinant DCC adenovirus was generated by a homologous recombination between pAdE1CMV/pA-DCC and the proviral vector pBHG10 in 293 cells. Once recombinant virus was formed, each viral clone was plaque-purified, amplified in 293 cells and characterized by genomic PCR (Kleinerman *et al.*, 1995). Three sets of primer were used separately. Primer set 1 (5'-CACTGAGGTGTCACAGGAA-3'; 5'-GTTCAA-GGGAGGAGTCCAAC-3') was

used for identifying the presence of the DCC cDNA insert. Primer set 2 (5'-TCGTTTCTCAGCAGCTGTTG-3'; 5'-CATCTGAACCTCA-AAGCGTGG-3') was used for identifying the presence of viral sequences. Primer set 3 (5'-ATTACCGAAGAAATGG-CCGC-3'; 5'-CCCATTAA-CACGCCATGCA-3') was used for examining the presence of E1 region. An absence of the E1 gene indicates that recombinant adenovirus stock is free of wild-type adenovirus contamination. AdCMV adenovirus was generated by a homologous recombination between the shuttle vector without cDNA insert and the proviral vector. The human Ad5 mutant d1312 is a replication-defective adenovirus due to the deletion of the E1 gene (Jones and Shenk, 1979). The AdCMV and d1312 adenovirus were used as controls. To construct AdDCCΔcyto, a PCR fragment that extends from a portion of the FN type III repeat to amino acid 1124 was used to replace the DCC cytoplasmic domain. The pcDNA-DCCΔcyto plasmid was sequenced to avoid possible PCR mis-incorporation. The AdDCCΔcyto was constructed with procedures described above.

### DNA fragmentation assay

Cells were collected and lysed in 200 µl of cold lysis buffer (20 mM Tris pH 7.4 10 mM EDTA 0.2% Triton X100) on ice for 15 min with vigorous vortexing every 5 min. The lysates were spun for 10 min in at 10 000 g. Supernatants were incubated with 50 µg/ml of DNase-free RNase A at 37°C for 1 h, then with 0.1 mg/ml of proteinase K, 0.1% SDS at 50°C overnight. Samples were extracted with phenol and chloroform. DNA was precipitated with ethanol, washed with 70% ethanol, dried and suspended in Tris-EDTA buffer. Samples were run on a 1.5% agarose gel.

### Nuclear staining

Cells were washed once in 1 µg/ml DAPI-methanol, stained in the DAPI-methanol solution at 37°C for 15 min, washed off the staining solution with methanol and mounted with anti-fade buffer.

### Immunostaining

Staining of DCC protein with peroxidase method was performed as described previously (Chen *et al.*, 1994). For immuno-fluorescent staining, cells were washed with PBS, fixed in 3.7% formaldehyde for 10 min and incubated with 0.2% BSA for 1 h to block non-specific binding. Samples were incubated with 20 µg/ml of anti-DCC antibody diluted in PBS-0.1% saponin for 1 h, washed with PBS, blocked with 5% normal donkey serum for 1 h and then incubated with 25 µg/ml donkey anti-mouse IgG conjugated with Texas red for 1 h. Samples were rinsed in PBS and mounted with anti-fade mounting buffer containing 75 ng/µl of DAPI. Cells were examined with Zeiss laser scan confocal microscope.

### Flow cytometry

Cell cycle distribution was analysed by flow cytometry as described previously (Chen *et al.*, 1995).

### Addition of netrin-1

Cells were mock-infected, or infected with d1312 or AdDCC at a MOI of five in the presence of 0, 0.3 and 3 µg/ml of netrin-1 protein, respectively.

### Bcl-2 expression

DU145 and DLD-1 cells were transfected with pcDNA3 or pcDNA Bcl-2-flag vector using lipofection method (25), and

selected with 400 µg/ml and 700 µg/ml of G418, respectively. Pooled population (>100 colonies) of Neo and Bcl-2 as well as individual colonies of Neo and Bcl-2 were obtained. Successful expression of the Bcl-2 protein was confirmed by Western blotting using anti-flag and anti-Bcl-2 antibodies. Functional expression of the Bcl-2 protein was determined by a protective effect of Bcl-2 on apoptosis induced by H<sub>2</sub>O<sub>2</sub>.

#### Cdk1 kinase assay

The activity of Cdk1 was measured by immunoprecipitation of Cdk1 with a polyclonal anti-Cdk1 antibody (Santa Cruz Biotechnology) following by H1 histone phosphorylation assay as described previously (Cipriano and Chen, 1998).

#### Sequence homology analysis

Possible sequence homology between the DCC cytoplasmic region and the death domain from Reaper, Fas, TNFR1, TRADD, FADD and RIP was analysed with the LaserGene software (DNASTAR, Inc.) on a Macintosh computer.

#### References

- Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB. (1993). *Cell*, **74**, 597–608.
- Chan SSY, Zheng H, Su MW, Wilk R, Killeen MT, Hedgecock EM and Culotti JG. (1996). *Cell*, **87**, 187–195.
- Chen YQ, Gao X, Grignon D, Sarkar F, Sakr W, Cipriano SC, Honn KV, Borders J and Crissman J. (1994). *Cancer Molec. Biol.*, **1**, 357–367.
- Chen YQ, Cipriano SC, Arenkiel JM and Miller FR. (1995). *Cancer Res.*, **55**, 4536–4539.
- Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman GA and Vogelstein B. (1994). *Genomics*, **19**, 525–531.
- Cipriano SC and Chen YQ. (1998). *Oncogene*, **17**, 1549–1556.
- Cleveland JL and Ihle JN. (1995). *Cell*, **81**, 479–482.
- Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A. (1992). *Nature*, **356**, 215–221.
- Dunphy WG. (1994). *Trends Cell Biol.*, **4**, 202–207.
- Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M and Weinberg RA. (1997). *Nature*, **386**, 796–804.
- Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW and Vogelstein B. (1990). *Science*, **247**, 49–56.
- Fearon ER. (1996). *Biochim. Biophys. Acta*, **1288**, 17–23.
- Fraser A and Evan G. (1996). *Cell*, **85**, 781–784.
- Gao X, Honn K, Grignon D, Sakr W and Chen YQ. (1993). *Cancer Res.*, **53**, 2723–2727.
- Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J and Mak TW. (1996). *Cell*, **85**, 1009–1023.
- Haldar S, Chintapalli J and Croce CM. (1996). *Cancer Res.*, **56**, 1253–1255.
- Hedrick L, Cho KR, Boyd J, Risinger J and Vogelstein B. (1992). *Cold Spring Harbor Sym. Quant. Bio.*, **57**, 345–351.
- Hunter T and Pines J. (1994). *Cell*, **79**, 573–582.
- Jones N and Shenk T. (1979). *Cell*, **17**, 683–689.
- Kaufman SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG. (1993). *Cancer Res.*, **53**, 3976–3985.
- Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SSY, Culotti JG and Tessier-Lavigne M. (1996). *Cell*, **87**, 175–185.
- King RW, Jackson PK and Kirschner MW. (1994). *Cell*, **79**, 563–571.
- Kleinerman DI, Zhang WW, Lin SH, Van NT, von Eschenbach AC and Hsieh JT. (1995). *Cancer Res.*, **55**, 2831–2836.
- Kolodziej PA, Timpe LC, Mitchell KJ, Fried SR, Goodman CS, Jan LY and Jan YN. (1996). *Cell*, **87**, 197–204.
- Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC. (1994). *Nature*, **371**, 346–347.
- Liu CY, Flesken-Nikitin A, Li S, Zeng Y and Lee WH. (1996). *Genes Dev.*, **10**, 1835–1843.
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL and Miller DK. (1995). *Nature*, **376**, 37–43.
- Nurse P. (1994). *Cell*, **79**, 547–550.
- Oltvai ZN and Korsmeyer SJ. (1994). *Cell*, **79**, 189–192.
- Sharan SK, Morimatsu M, Albrecht U, Lim D, Regel E, Dinh C, Sands A, Eichele G, Hasty P and Bradley A. (1997). *Nature*, **386**, 804–810.
- Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM. (1995). *Cell*, **81**, 801–809.
- Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Wilson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW and Vogelstein B. (1996). *Nature Genetics*, **13**, 343–346.
- White E. (1996). *Genes Dev.*, **10**, 1–15.

#### Abbreviations

Cdk, cyclin-dependent kinase; DAPI, 4', 6-Diamidine-2'-Phenylindole Dihydrochloride; DMEM, Dulbecco modified minimum essential medium; EGF, epidermal growth factor; Ig, immunoglobulin; MOI, multiplicity of infection; FBS, fetal bovine serum; PARP, poly (ADP-ribose) polymerase.

Tuesday, September 21, 1999 3:12 PM

Appendix 2

cDNA sequence of Dip5

Unpublished data

10 20 30 40 50 60 70  
  
ggcacgaggtaatctgggtgtaaatctggatgtaccattggattggagacatacATGCATCGGATTGG 70  
GAGAGCTGGCGTTTGGTACATTGGGCTGACAGTGACCTACTGTTGCCGGGAGAGGAAGAAAATATG 140  
ATGATGAGAATTGCCAGAAATGTAATATCAACCTCTCCCTTACCAAGATCCCATTCCCTCTGGTCTGA 210  
TGGAAAGAATGTGIGGATTGGATGTGGAAAGTTAAAGCTGCTGTGCATACATATGGTATAGCAAGITGACC 280  
TAACCAACCTTAAAAAAGCAAATTCAAGAAAATAGAGAGAACCCCTCAAATTCAAGAAAGCTCATGGTGCAC 350  
CACATGGCTTCCTCTAGAAATAATTCTGTATCTGGACTATCAGTCAAATCAAAAAATAATACCAAACAAA 420  
AGCTTCCCTGIGAAAAGCCACTCAGAATGTGGAATCATAGAAAAGCAACGTACCAAAAGAACTGGCTG 490  
TGACAGGCAATCCGAAGAGCAAATGAAGAATTCTGTCAGACTCCCGTTGAAAACCTCCACCAACAGTCAG 560  
CACCAGGTCAAAGAAGCTTACCTGTGTCACTCCCCCAGATTCCCTGCTGCTTCCTTAAATCCATC 630  
AGCCATACACGTGACTTTGCTGAATTGGTAGAGGATTATGAACATTATATTAAAGAGGGGTAGAGAA 700  
ACCTGTGAAATCATCAGGCACTACACAGGCCCTGGGATCAGACTGTGAATCCTCAAATGGTTTG 770  
AGAAATAAAGTTATTGAACAGAGAGTCCCTGTGTTGCAAGTAGTACGCAATCTGGAGACTCTGAGAGTG 840  
ACAGTGATTCTACAGCTCAAGAACCTCTCCAGAGCAAAGGAAATAAGTCATACTTGGAAAGGCTCTC 910  
TGATAATCAGCTGAAAGACTCTGAATCTACGCTGTGGATGATCGTATTCTTGGAAACAACCACCAAAT 980  
GGAAGTGACACCCCCAATCCAGAGAAATATCAAGAAATCACCTGGAATCCAGATGAAGACAAGACTAAAG 1050  
AGGGGGCTAGCCAGAGAGCTAACGAGAGCCGGAGAACCTACCCAGGCGGCTTCCTCAGATTGAGAC 1120  
TGAAGCCCAGGAAGATGATGGTATGACTGTGATAGGGAAATACGTCIGAGTTTCTGATACCTATCAG 1190  
GATTATGAGGAGTACTGGAGAGCTTACTACAGGGCATGGCAAGAATAATTATGCTGCCGCTCTCATTATC 1260  
ATTATTGGAATGCTCAGAGACATCCAAGTGGATGGCAGCTTATCACATGAATACCATTATCTACAAGA 1330  
AATGATGCATAGTAACCAGTGAttataggatataccctgagaccatcaggaactgtcaacaaatgatacc 1400  
ttggatatccatcctcctcgacttatagtacagtgggtatagtggcatttctgataaacttgaaaagac 1470  
ttgagtcttccactggacacatccatttcagattgtttgatttaggccaggtatattatcttcatt 1540  
tttaagatttcttaagaaacttcatcagattgttggaaagataattttggacatagagctgaaagt 1610  
ttcagggtgccatttctataagatctccaaaagaaacattaaaaagatgacatataccaccactta 1680  
ctaaaaacaataaaagcaatagattgatttagtaaaaaaaaaaaaaaaac 1735

Tuesday, September 21, 1999 3:14 PM

Appendix 3

cDNA sequence of Dip13

Unpublished data

10 20 30 40 50 60 70  
ggcacgagaggccctcccccaaataactacacctaggcttccaattgtctgactccccctgggtaggggga 70  
gctcctgtgtgaagatcagcctggccaggcaaaagccttggccagggaggcaggcgtaaaaatccat 140  
ttggagaatctggaggaagtacaaaaatctgaaactgaagattctattcttcattcagttatttattgtccg 210  
attccttggttcaATGGAGGTGAAATCAGATGACCATCCAGATGTTATGAAACTATGCGCAAATC 280  
TTAGCTGCCCGGCCATCCATAACATCTTCGTATGACAGAACCGCATTATTAGTCACTTGTGACTGTT 350  
TAAAGTTAATTGATCCACAGACACAAGTTACAAGGCTCACGTTCCATTACCTTGTTAGTTGATGC 420  
TACACACCAGGAAAATAAGCGCCTTTGGATTGTTGCTTCGGACATCAAGCGGGAGAAGTGAAGTAAT 490  
CTGTCATCAGTCAGTCTGCTATATATTGAGTCAAACAATGAGGGGAAAAGATAATGTGATTCTGTGGACTGG 560  
CAAAACAGATAGCCTTGCACTGCTGAACGGATCGTAGGGCATCAGAAAAACAAAAAGAAATAGAGAGAT 630  
AAAAGAGAAGCAACAGAAAGAACTCAATAAACAAAACAGATTGAAAGGACTTCCAAGAACAAAGTCGG 700  
TTGATAGCTGCTTCCAGTAGACCAAACCAAGCCAGTAGTGAGGGCAGTTGTTGTCCTAGCAGTAGCC 770  
AGTCAGAAGAGAGTGATTGGAGAAGGAGGAAAGAAGAGAGAATCAGAAGCATAAgcttataactttgg 840  
taaatattcccccttggatttgacagttctatggtaaatggcagaaggtaacaactatgttaata 910  
tcaaggaggagattaagcttatattgcctaattgttagctacattttaaaaaaaaagattgaacttg 980  
atgacttaagttgcattgatctttcccccttaaacataatgtactatgttataacatcctaaaggga 1050  
acctgctcatctccctgaagcagactgctgaagaaatcacattgctcaagaattttccgtcaaattgt 1120  
gaacttttaattcctgcaattgttaattggctgtgccataggaatcatttattcttcaggcttagacatt 1190  
catggatatgctttcttcatttaggaacatttgctggatgaggaagcatttagctgaataagttta 1260  
aagcccttataccggaattctacaagttgcaaatatttaacaatattaaatgtcaatagaactttt 1330  
ttaaaataatttggAACGGGATTTCAGTTAAGGTTCAATTGTGGCAGGTGGTACTGTTGATCTCAGG 1400  
gtactttctggattgctcacattctctaattgtactgcacttgatgccagtcggaaagaagcttaagt 1470  
tcttcagttcaagattgatagagcccttggcattttattatcacattcttagttctcagggtggacttc 1540  
aattactgctgcagagccgtagtggtaaaaaataagatatttggaaatttattaaaagattttgttcaata 1610  
catttttagattaggattgacaagtaaagatactgctatggaaatgtaaaaaaaaaaaaaaaaaaaaaa 1680  
aactcgag 1688



**DEPARTMENT OF THE ARMY**  
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND  
504 SCOTT STREET  
FORT DETRICK, MARYLAND 21702-5012

REPLY TO  
ATTENTION OF:

MCMR-RMI-S (70-1y)

7  
5 Mar 02


MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statements

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for grants. Request the limited distribution statements for Accession Documents listed at enclosure be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.
2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl



PHYLLIS M. RINEHART  
Deputy Chief of Staff for  
Information Management

DISTRIBUTION TO BE CHANGED TO UNLIMITED,  
APPROVED FOR PUBLIC RELEASE

ACCESSION DOCUMENT NUMBERS

|           |           |
|-----------|-----------|
| ADB267943 | ADB267947 |
| ADB257308 | ADB268439 |
| ADB233733 | ADB242952 |
| ADB263445 | ADB248375 |
| ADB258807 | ADB240661 |
| ADB257354 | ADB271166 |
| ADB240907 | ADB258706 |
| ADB270764 | ADB244250 |
| ADB241926 | ADB258773 |
| ADB246527 | ADB254490 |
| ADB268422 | ADB268189 |
| ADB252915 | ADB270793 |
| ADB258877 | ADB266144 |
| ADB268117 | ADB236672 |
| ADB267884 | ADB259031 |
| ADB254260 | ADB270765 |
| ADB268296 | ADB270785 |
| ADB258930 | ADB268113 |
| ADB271098 | ADB270791 |